Ashland Inc. (ASH) SEC Filings & Earnings Calls
EquiReason read 22 Ashland Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Ashland amended its European accounts receivable securitization facility, extending maturity to Sept 2029, with €125M limit. No new borrowing amount; routine amendment..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 3.3B
- P/E TTM
- 69.5
- Dividend yield
- 2.2%
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
25 Sep 20268-K · 1.01, 2.03Ashland amended its European accounts receivable securitization facility, extending maturity to Sept 2029, with €125M limit. No new borrowing amount; routine amendment.open
Risks flagged
No new risk; routine amendment extending maturity of existing securitization facility.
“Amendment extends the scheduled termination date” · word for word
31 Jul 20268-K · 1.01, 2.03Ashland amended its receivables securitization facility, extending maturity to July 2028 and maintaining $70M commitments; routine refinancing with no material change in terms.open
Figures in the filing · each found in the filing text
| amount_facility · Q3-2026 | $70M |
29 Jul 202610-QAshland reported Q3 FY2026 results with sales up 7.3% YoY, gross margin expansion of 5.7pp, but Adjusted EBITDA down 3.5% due to higher costs.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2026 | $497M | +7% y/y |
| Gross Profit as a percent of sales · Q3-2026 | 34.2% | |
| Adjusted EBITDA · Q3-2026 | $109M | -4% y/y |
| Net income (loss) · Q3-2026 | $16M | -102% y/y |
| Diluted EPS from continuing operations · Q3-2026 | $0.89 | -106% y/y |
| Adjusted Diluted EPS from Continuing Operations Excluding Intangibles Amortization Expense · Q3-2026 | $1.02 | -2% y/y |
| Life Sciences Sales · Life Sciences · Q3-2026 | $180M | +11% y/y |
| Personal Care Sales · Personal Care · Q3-2026 | $155M | +5% y/y |
| Specialty Additives Sales · Specialty Additives · Q3-2026 | $136M | +4% y/y |
| Intermediates Sales · Intermediates · Q3-2026 | $37M | +12% y/y |
Risks flagged
Tariff and Trade Policy Risk
“Beginning in the second quarter of fiscal 2025, the U.S. instituted a series of tariffs on imports from China, the E.U., India, and other countries which has resulted in the imposition of retaliatory measures against U.S. goods.”
Geopolitical Conflict Risk
“Business disruptions, including those related to the ongoing conflicts between the United States, Israel/Iran, Ukraine/Russia and Israel/Hamas, as well as the recent political events in Venezuela, continue to impact businesses around the globe.” · word for word
Goodwill Impairment Risk
“Ashland recorded a $706 million goodwill impairment charge during the three months ended June 30, 2025.” · word for word
28 Jul 20268-K · 2.02, 7.01Sales $497M (+7% y/y); Adjusted EBITDA $109M (-4% y/y); Income from continuing operations $41M; Guidance: Sales $1,835-$1,870M; Adjusted EBITDA $385-$400Mearningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2026 | $497M | +7% y/y |
| Adjusted EBITDA · Q3-2026 | $109M | -4% y/y |
| Income from continuing operations · Q3-2026 | $41M | |
| Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense · Q3-2026 | $47M | -2% y/y |
| Net income · Q3-2026 | $16M | |
| Cash flows provided by operating activities · Q3-2026 | $121M | +6% y/y |
| Ongoing Free Cash Flow · Q3-2026 | $103M | -5% y/y |
Guidance
Sales $1,835-$1,870M; Adjusted EBITDA $385-$400M
Reaffirmed full-year guidance with positive demand commentary but margin pressure from costs.
Risks flagged
Margin pressure from lower production rates and inflationary costs.
“Adjusted EBITDA down 4% YoY despite sales growth; inflationary cost pressures and normalization of incentive compensation.”
28 Jul 20268-K · 1.01, 5.02, 7.01Ashland entered a cooperation agreement with Ancora Holdings Group, appointing two new directors and forming a Capital Allocation Advisory Committee, indicating activist engagement.open
Risks flagged
Potential shift in capital allocation strategy due to activist influence.
“Formation of Capital Allocation Advisory Committee and activist standstill agreement.”
29 May 20268-K · 1.01, 2.03Ashland entered a $500M unsecured revolving credit facility (5-yr) to replace prior facility, with standard covenants and pricing grid based on leverage. Refinancing of existing credit line, no new net debt.open
Figures in the filing · each found in the filing text
| Revolving credit facility · Q2-2026 | $500M |
Risks flagged
Covenants include maximum leverage and minimum interest coverage; potential constraint if earnings decline.
“financial covenants (including maintenance of a maximum Consolidated Net Leverage Ratio and a minimum Consolidated Interest Coverage Ratio).” · word for word
18 May 2026SC 13D/AStandard Investments LLC increased its activist stake in Ashland Inc. to 8.943% and total economic exposure to 9.88%.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-05-15 | 8.9% | |
| Economic Exposure Percentage · 2026-05-15 | 9.9% |
Risks flagged
Activist-driven change risk
“The Reporting Persons acquired additional Shares as disclosed in Item 5(c) below because they believe the Shares represent an attractive investment opportunity.” · word for word
18 May 2026SC 13D/AStandard Investments LLC increased its activist stake in Ashland Inc. to 8.943% and total economic exposure to 9.88%.open
Figures in the filing · each found in the filing text
| Beneficial Ownership Percentage · 2026-05-15 | 8.9% | |
| Economic Exposure Percentage · 2026-05-15 | 9.9% |
Risks flagged
Activist-driven change risk
“The Reporting Persons acquired additional Shares as disclosed in Item 5(c) below because they believe the Shares represent an attractive investment opportunity.” · word for word
6 May 2026SC 13D/AStandard Investments LLC filed an amended Schedule 13D disclosing an increased passive stake of 6.803% in Ashland Inc. and total economic exposure of ~9.89%.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-05-05 | 6.8% | |
| Total economic exposure percentage · 2026-05-05 | 9.9% | |
| Total purchase price · 2026-05-05 | $159M |
6 May 2026SC 13D/AStandard Investments LLC filed an amended Schedule 13D disclosing an increased passive stake of 6.803% in Ashland Inc. and total economic exposure of ~9.89%.open
Figures in the filing · each found in the filing text
| Beneficial ownership percentage · 2026-05-05 | 6.8% | |
| Total economic exposure percentage · 2026-05-05 | 9.9% | |
| Total purchase price · 2026-05-05 | $159M |
29 Apr 202610-QSales $482M (+1% y/y); Net income $16M (-48% y/y); Adjusted EBITDA $98M (-9% y/y)open
Figures in the filing · each found in the filing text
| Sales · Q2-2026 | $482M | +1% y/y |
| Net income · Q2-2026 | $16M | -48% y/y |
| Adjusted EBITDA · Q2-2026 | $98M | -9% y/y |
| Gross profit margin · Q2-2026 | 30.5% | |
| Operating cash flow from continuing operations · H1-2026 | $175M |
Risks flagged
Tariff and trade policy uncertainty
“As a global business, we are exposed to risks associated with tariffs and other trade conflicts.” · word for word
Operational disruptions (Calvert City startup delay, weather)
“The decrease in Adjusted EBITDA was primarily driven by softer pricing, the Calvert City startup delay and weather-related operational disruptions during the quarter.”
Geopolitical conflict exposure
“Business disruptions, including those related to the ongoing conflicts between the United States, Israel/Iran, Ukraine/Russia and Israel/Hamas, as well as the recent political events in Venezuela, continue to impact businesses around the globe.” · word for word
28 Apr 20268-K · 2.02, 7.01Sales $482M (+1% y/y); Income from continuing operations $15M; Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense $42M; Guidance: Sales guidance lowered to $1,835-$1,870M; EBITDA to $385-$400Mearningsopen
Figures in the filing · each found in the filing text
| Sales · Q2-2026 | $482M | +1% y/y |
| Income from continuing operations · Q2-2026 | $15M | |
| Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense · Q2-2026 | $42M | |
| Net income · Q2-2026 | $16M | |
| Adjusted EBITDA · Q2-2026 | $98M | -9% y/y |
| Cash flows provided by operating activities · Q2-2026 | $50M | |
| Ongoing Free Cash Flow · Q2-2026 | $29M |
Guidance
Sales guidance lowered to $1,835-$1,870M; EBITDA to $385-$400M
Guidance cut due to operational issues at Hopewell; demand generally resilient but margins under pressure.
Risks flagged
Operational issues at Hopewell plant causing productivity delays and margin pressure
“Hopewell productivity challenges; slower than expected ramp; Adjusted EBITDA -9%”
Weather-related disruptions and Middle East supply chain disruptions impacting operations
“Weather-related disruptions in Q2; March supply chain disruptions related to Middle East geopolitical tensions”
3 Feb 202610-QSales $386M (-5% y/y); Gross profit as a percent of sales 27.2; Adjusted EBITDA $58M (-5% y/y); Guidance: FY2026 Adjusted EBITDA guidance narrowed to $400-420M from $400-430M; $11M temporary impact from Calvert City startup delay and weatheopen
Figures in the filing · each found in the filing text
| Sales · consolidated · Q1-2026 | $386M | -5% y/y |
| Gross profit as a percent of sales · consolidated · Q1-2026 | 27.2% | |
| Adjusted EBITDA · consolidated · Q1-2026 | $58M | -5% y/y |
| Net loss · consolidated · Q1-2026 | $-12M | +93% y/y |
| Diluted EPS from continuing operations · continuing_operations · Q1-2026 | $-0.30 | +92% y/y |
| Adjusted Diluted EPS from Continuing Operations Excluding Intangibles Amortization Expense · continuing_operations · Q1-2026 | $0.26 | -7% y/y |
| Operating cash flow from continuing operations · continuing_operations · Q1-2026 | $125M | +517% y/y |
| Free Cash Flow · continuing_operations · Q1-2026 | $111M | +309% y/y |
| Capital expenditures · continuing_operations · Q1-2026 | $14M | -39% y/y |
| Life Sciences sales · Life Sciences · Q1-2026 | $139M | +4% y/y |
Guidance
FY2026 Adjusted EBITDA guidance narrowed to $400-420M from $400-430M; $11M temporary impact from Calvert City startup delay and weather disruptions
Full-year Adjusted EBITDA guidance narrowed by $10M at the high end; temporary Q2 impacts from operational disruptions; core end markets resilient; cost savings on track.
Risks flagged
Tariff and trade policy uncertainty
“As a global business, we are exposed to risks associated with tariffs and other trade conflicts. Such risks may include, but are not limited to, (i) changes to and strains on the global supply chain and our ability to source materials; (ii) increased sourcing and manufacturing costs; (iii) decreased demand for Ashland’s products in affected markets.” · word for word
Geopolitical conflict risk
“Business disruptions, including those related to the ongoing conflicts between Israel/Iran, Ukraine/Russia and Israel/Hamas, as well as the recent political events in Venezuela, continue to impact businesses around the globe.” · word for word
Execution risk on manufacturing optimization
“Ashland is also advancing a multi-year manufacturing network optimization to improve operational cost and strengthen its competitive position. This optimization plan is expected to generate pre-tax savings of $50 million to $55 million with $60 million being achievable as market conditions improve, particularly within China.” · word for word
Calvert City startup delay and weather disruption
“The updated outlook reflects approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions, all isolated to the second quarter.” · word for word
2 Feb 20268-K · 2.02, 7.01Sales $386M (-5% y/y); Loss from continuing operations $-14M; Adjusted EBITDA $58M (-5% y/y); Guidance: Narrowed to $400-$420M from prior range; ~$11M temporary impactearningsopen
Figures in the filing · each found in the filing text
| Sales · Q1-2026 | $386M | -5% y/y |
| Loss from continuing operations · Q1-2026 | $-14M | |
| Adjusted EBITDA · Q1-2026 | $58M | -5% y/y |
| Cash flows provided by operating activities · Q1-2026 | $125M | |
| Ongoing Free Cash Flow · Q1-2026 | $26M | |
| Adjusted Income from Continuing Operations Excluding Intangibles Amortization Expense · Q1-2026 | $12M | -14% y/y |
Guidance
Narrowed to $400-$420M from prior range; ~$11M temporary impact
Full-year Adjusted EBITDA guidance narrowed to $400-$420M, reflecting temporary impacts from Calvert City startup delay and weather disruptions, isolated to Q2. Underlying demand mixed with Life Sciences growth offset by weakness in Specialty Additives and Intermediates.
Risks flagged
Calvert City startup delay and weather disruptions causing temporary EBITDA impact of ~$11M, isolated to Q2.
“approximately $11 million of temporary impacts from the Calvert City startup delay and recent weather-related disruptions, isolated to the second quarter” · word for word
Mixed demand conditions with weakness in Specialty Additives and Intermediates segments.
“softer demand in coatings, construction, and select industrial markets... Intermediates continues to navigate trough-like conditions” · word for word
Competitive intensity in Specialty Additives pressuring volumes and pricing.
“ongoing competitive intensity and softer demand in coatings, construction, and select industrial markets” · word for word
9 Dec 2025DEF 14AAshland filed its definitive proxy statement for the 2026 annual meeting, disclosing executive compensation details, governance practices, and performance metrics.open
Figures in the filing · each found in the filing text
| Sales · FY2025 | $1.82B | -14% y/y |
| Adjusted EBITDA · FY2025 | $401M | -13% y/y |
| Adjusted EBITDA margin · FY2025 | 22.0% | |
| Adjusted EPS (excluding intangible amortization) · FY2025 | $3.38 | -24% y/y |
| Ongoing FCF · FY2025 | $127M | -53% y/y |
| Net income (loss) · FY2025 | $-845M | |
| Operating income (loss) · FY2025 | $-775M | |
| Goodwill impairment · FY2025 | $706M | |
| Restructuring savings · FY2025 | $30M | |
| Stock repurchases · FY2025 | $100M |
Risks flagged
Goodwill impairment risk
“Operating loss in fiscal 2025 included a $706 million goodwill impairment charge.” · word for word
Portfolio optimization execution risk
“Portfolio Optimization initiatives including the curtailment or divestiture of lower margin products, reduced sales by approximately $208 million, or ten percent.” · word for word
Demand and pricing pressure
“Adjusted EBITDA of $401 million in fiscal 2025, down from $459 million in fiscal 2024, reflecting the impact of Portfolio Optimization, lower pricing, and reduced volumes.” · word for word
20 Nov 202510-KSales $1.82B (-14% y/y); Net income (loss) $-845M; Adjusted EBITDA $401M (-13% y/y)open
Figures in the filing · each found in the filing text
| Sales · FY2025 | $1.82B | -14% y/y |
| Net income (loss) · FY2025 | $-845M | |
| Adjusted EBITDA · FY2025 | $401M | -13% y/y |
| Gross profit as a percent of sales · FY2025 | 30.1% |
Risks flagged
Goodwill impairment risk realized
“resulting in non-cash goodwill impairment charges of $375 million and $331 million, respectively, for a total goodwill impairment charge of $706 million” · word for word
Tariff and trade policy uncertainty
“Such risks may include, but are not limited to, (i) changes to and strains on the global supply chain and our ability to source materials; (ii) increased sourcing and manufacturing costs; (iii) decreased demand for Ashland’s products in affected markets” · word for word
Geopolitical conflict exposure
“Sales to Israel, Ukraine, Russia, and Belarus represent less than 1% of total consolidated sales and less than 1% of total consolidated assets” · word for word
4 Nov 20258-K · 2.02, 7.01Sales $478M (-8% y/y); Net income $32M (+100% y/y); Adjusted EBITDA $119M (-4% y/y)earningsopen
Figures in the filing · each found in the filing text
| Sales · Q4-2025 | $478M | -8% y/y |
| Net income · Q4-2025 | $32M | +100% y/y |
| Adjusted EBITDA · Q4-2025 | $119M | -4% y/y |
| Cash flows provided by operating activities · Q4-2025 | $40M | -50% y/y |
| Ongoing Free Cash Flow · Q4-2025 | $52M | -41% y/y |
Risks flagged
Portfolio optimization reduces sales and EBITDA, indicating strategic shift away from lower-margin products
“Portfolio Optimization initiatives reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter”
Muted demand in China and North America, competitive pressure in MEAI
“Demand remained soft in China and North America, contributing to a year-over-year decline, with elevated competitive intensity in MEAI.” · word for word
Ashland Inc. — questions
- What did Ashland Inc. file recently?
- 22 SEC filings in the last 12 months. Latest: 8-K on 2026-09-25 — Ashland amended its European accounts receivable securitization facility, extending maturity to Sept 2029, with €125M limit. No new borrowing amount; routine amendment.
Every figure on this page comes from Ashland Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.